In this study, we have developed fluorescent-labelled dual-targeted MPIO (DT-MPIO) against P-selectin and VCAM-1 as a dual-imaging modality contrast agent for the following: (i) in vivo MR imaging of inflammation in atherosclerosis and (ii) ex vivo optical imaging for subsequent histological validation. This evidence concerns the gene SELP and atherosclerosis.